Background: Piroxicam is a non-steroidal anti-inflammatory drug belongs to BCS class II drugs having poor solubility and is associated with a number of undesirable side-effects on the stomach and kidneys in addition to gastric mucosal damage.
Aim: The present work was to develop and characterize nanoemulgel formulation as transdermal delivery system for poorly water soluble drug, in order to overcome the troubles associated with its oral delivery and to circumvent the need of chemical penetration enhancers, which are responsible for causing skin irritation in transdermal drug delivery.
Materials And Methods: Different nanoemulsion components (oil, surfactant and co-surfactant) were selected on the basis of solubility and emulsification ability. Pseudoternary phase diagrams were constructed using aqueous titration method to figure out the concentration range of components. Carbopol 934 was added as gel matrix to convert nanoemulsion into nanoemulgel. Drug loaded nanoemulsions and nanoemulgels were characterized for particle size, transmission electron microscopy, viscosity, conductivity, spreadability, rheological behavior, permeation studies using Wistar rat skin and stability studies. Transdermal permeation of piroxicam from nanoemulgels was determined by using Franz Diffusion cell.
Results: The optimized nanoemulgel (BG6) contained 10% oleic acid as oil, 35% tween 80 and ethanol as surfactant co-surfactant mixture, 55% water, 0.5% drug and 0.5% w/w carbopol. The ex vivo permeation profile of optimized formulation was compared with nanoemulsion and marketed formulation (Feldene(®)). Nanoemulgel showed higher (P < 0.05) cumulative amount of drug permeated and flux and significantly less drug retained along with less lag time than marketed formulation.
Conclusion: The results indicate that nanoemulgel formulation can be used as a feasible alternative to conventional formulations of piroxicam with advanced permeation characteristics for transdermal application.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4083536 | PMC |
http://dx.doi.org/10.4103/2230-973X.133053 | DOI Listing |
Int J Nanomedicine
January 2025
Department of Pharmaceutical Sciences, School of Pharmacy, Lebanese American University, Byblos, Lebanon.
Introduction: Androgenetic alopecia (AGA) is a multifactorial and age-related dermatological disease that affects both males and females, usually at older ages. Traditional hair repair drugs exemplified by minoxidil have limitations such as skin irritation and hypertrichosis. Thus, attention has been shifted to the use of repurposing drugs.
View Article and Find Full Text PDFPathophysiology
November 2024
Pharmaceutical Nanotechnology Research Laboratory, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Ministry of Chemicals and Fertilizers, Government of India, Hyderabad 500037, Telangana, India.
To investigate the anti-inflammatory, antioxidant, and diabetic wound healing properties of the novel topical formulation [Ferulic acid-loaded nanoemulgel (DLMGO-G)]. Ferulic acid nanoemulsion developed with lemongrass oil is investigated in diabetic wound healing. Further nanoemulsion is incorporated into 1% carbopol 934 to obtain the DLMGO-G.
View Article and Find Full Text PDFADMET DMPK
November 2024
Department of Pharmaceutics, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq.
Background And Purpose: Cellulite is caused by changes in the metabolism of the fatty tissue beneath the skin. Methylxanthines and retinoids are commonly added to the different anticellulite products. However, their topical permeation into the dermis is limited.
View Article and Find Full Text PDFInt J Nanomedicine
December 2024
Laboratory of Chemical, Galenic and Pharmacological Development of Medicines (LR12ES09), Faculty of Pharmacy of Monastir, University of Monastir, Monastir, Tunisia.
Background: Phosphodiesterase-4 is an enzyme that regulates immune responses and contributes to the development of psoriasis. Dipyridamole and roflumilast function as phosphodiesterase-4 inhibitors, reducing pro-inflammatory cytokine expression. The aim was to evaluate the anti-psoriatic effect of the topical administration of dipyridamole and roflumilast nanoemulgel combination on imiquimod-induced psoriasiform skin inflammation in rats.
View Article and Find Full Text PDFExpert Opin Drug Deliv
January 2025
Industrial Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science, Pilani (BITS-PILANI), Pilani, India.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!